Table 1 Study characteristics of published literature on the impact of compliance on health outcome and health-related quality of life on thalassaemia patients
Author, Year | Country | Sample size | Centre | Study Design | Iron Chelation Therapy | Duration |
|---|---|---|---|---|---|---|
Wolfe et al. 1985 [33] | United States | 36 | Multi | Prospective cohort | DFO | 6 years |
Al-Refaie et al. 1992 [17] | United Kingdom | 52 | N/A | Cross sectional | DFO | N/A |
Richardson et al. 1993 [34] | Australia | 76 | Single | Retrospective cohort | DFO | N/A |
Arboretti et al. 2001 [18] | Italy | 867 | Multi | Cross sectional | DFO | Period 1: 5 months Period 2: 6 months |
Kidson-Gerber et al. 2008 [19] | Australia | 44 | Single | Phase 1: Cross sectional Phase 2: Retrospective | DFO (n = 43), DFP (n = 18), DFO & DFP (n = 17) | 1 year |
Lee et al. 2011 [20] | Malaysia | 139 | Single | Cross sectional | DFO | 1 year |
Haghpanah et al. 2013 [21] | Iran | 101 | Single | Cross sectional | DFO | N/A (2009) |
Mokhtar et al. 2013 [35] | Egypt | 447 | Single | Retrospective cohort | DFO (n = 99), DFP (n = 119), DFX (n = 21) and DFO& DFP (n = 208) | N/A |
Haghpanah et al. 2014 [22] | Iran | 220 | Single | Cross sectional | DFO (n = 114), DFX (n = 106) | N/A (2012) |
Elalfy et al. 2014 [36] | Egypt | 96 | Multi | Prospective randomized controlled trial | Group A: DFO & DFP (n = 48) Group B: DFP & DFX (n = 48) | 1 year |
Sobota et al. 2014 [23] | US, Canada, and the UK | 264 | Multi | Cross sectional | DFO (n = 57), DFP (n = 136), DFX (n = 9), DFO & DFP (n = 21) and DFO & DFX (n = 17), patients with no chelation (n = 22) Patients on no chelation were excluded from some analyses that focused on chelator choice. | N/A |
Bazi et al. 2017 [24] | Iran | 80 | Single | Cross sectional | N/A Monotherapy (n = 62) and combinational regimen (n = 18) | N/A |
Sobhani et al. 2019 [25] | Iran | 90 | Single | Cross sectional | DFO (n = 52), DFX (n = 29), DFO & DFX (n = 9) | 1 year |
Yassouf et al. 2019 [26] | Syria | 82 | Single | Cross sectional | DFO | 3 months |
Sukhmani et al. 2020 [27] | India | 215 | Single | Cross sectional | DFO, DFP, DFX and combination therapy 57.2% of patients (n = 123) were on monotherapy and 42.7% of patients (n = 92) on combinational therapy of two or more iron chelators. | N/A |
Theppornpitak et al. 2021 [28] | Thailand | 70 | Single | Prospective cross sectional | DFP (n = 49), DFX (n = 14), DFO (n = 2) | 5 months |
Badur et al. 2021 [32] | Turkey | 27 | Single | Prospective cross sectional | N/A | N/A |
Mahmoud et al. 2021 [29] | Egypt | 120 | Single | Cross sectional | DFX, DFO or both | 2 years |
Chai et al. 2021 [30] | Malaysia | 198 | Multi | Prospective cross sectional | DFO (n = 32), DFP (n = 60), DFX (n = 73), DFO & DFP (n = 20), DFO & DFX (n = 13) | 1 year |
Lam et al. 2021 [31] | Singapore | 73 | Multi | Ambidirectional cross sectional study Retrospective reviews of clinical information and prospective interview patients/caregivers for socioeconomic data and compliance | 38.2% of subjects were on monotherapy with DFX, 17.6% on DFP, 8.8% on DFO and 35.3% were on combination therapy. | 2.5 years |